This is now in an active data gathering phase. As osteosarcoma is a rare cancer, obtaining suitable biospecimens is a major obstacle to studying this disease. To overcome this problem it has been necessary to reach outside of the intramural community. A collaboration to obtain specimens has been established with the Childrens Oncology Group (COG), the primary national cooperative clinical trials group for pediatric cancer, to sequence specimens collected under COG trial. As osteosarcoma had been selected by the TARGET project (NCIs Therapeutically Applicable Research to Generate Effective Treatments, http://target.cancer.gov/about/), the TARGET infrastructure has been used to facilitate the COG collaboration. This collaboration will provide samples for analysis. An additional aspect of the early phase of this project has been the development of the necessary sequencing and bioinformatics infrastructure. Suitable sequencing and computational equipment has been installed to support this project, and the bioinformatics infrastructure for data analysis has also been developed. Data generation has been completed on a panel of osteosarcoma cell lines. This will be highly useful for the long term goals of the project since well characterized cell lines can be used for functional investigation of the biologically important results obtained in the course of this research. We have now initiated the analysis of clinical biospecimens collected through the TARGET program. This entails the sequencing of exomes, transcriptomes, and, from selected specimens, whole genomes. A large proportion of the data has been collected, and is now entering the analysis phase. Analysis will use standard and novel methods. This will be followed by technical validation, prevalence determination, and biological investigation of principle leads arising from this discovery phase.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011328-04
Application #
8763458
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
2013
Total Cost
$1,396,500
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Nakka, Manjula; Allen-Rhoades, Wendy; Li, Yiting et al. (2017) Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma. Oncotarget 8:96738-96752
Gindin, Yevgeniy; Jiang, Yuan; Francis, Princy et al. (2015) miR-23a impairs bone differentiation in osteosarcoma via down-regulation of GJA1. Front Genet 6:233
Mirabello, Lisa; Koster, Roelof; Moriarity, Branden S et al. (2015) A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. Cancer Discov 5:920-31
Khanna, Chand; Fan, Timothy M; Gorlick, Richard et al. (2014) Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res 20:4200-9
Savage, Sharon A; Mirabello, Lisa; Wang, Zhaoming et al. (2013) Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet 45:799-803